Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Early and Severe Systemic Sclerosis
NCT00379431Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Nov 2006
- Primary completion
- Feb 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in systemic sclerosis (SSc), sponsored by Ghent University Hospital. Primary endpoints: Death at 28 weeks, Heart failure defined as a LVEF < 30% at 28 weeks and 7 more. Started Nov 2006; status: completed.
02
Drugs
rituximab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT00379431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00379431.